This Week in Cardiology cover image

Nov 18, 2022, This Week in Cardiology

This Week in Cardiology

00:00

Are Iron Infusions Worth the Trouble?

No iron man must be considered a trial with a non significant primary endpoint. More important endpoints like CV death and all cause hospitalizations or even quality of life were not different. The weakness of this Iron Man data also informs payers. In a system where cost is no issue, sure, go ahead, offer an iron infusions. But this includes exactly zero health systems.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app